Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study - Report - MDSpire

Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study

  • By

  • Oliver Kriege

  • Boris Böll

  • Nicole Brüder

  • Nicola Giesen

  • Julia Lanznaster

  • Susanne Mertins

  • Antrea Minti

  • Jan-Hendrik Naendrup

  • Martin Schmidt-Hieber

  • Ruth Seggewiss-Bernhardt

  • Philipp Weber

  • Kai Wille

  • Jens Panse

  • Marcus Hentrich

  • Enrico Schalk

  • July 10, 2026

Share

Clinical Report: Reducing Central Venous Catheter Duration in Male Patients

Overview

This study investigates the impact of reducing central venous catheter (CVC) duration on the rate of catheter-related bloodstream infections (CRBSI) in male patients with hematological and oncological disorders.

Background

Bloodstream infections (BSI) are a significant concern in patients with cancer, particularly those with hematological malignancies. Men are more susceptible to BSIs, with higher mortality rates compared to women. Central venous catheters (CVC) are a common source of BSIs.

Data Highlights

No numerical data available in the provided source material.

Key Findings

  • Men with hematological malignancies have a higher rate of CRBSI compared to women (9.9% vs. 6.7%; p = 0.002).
  • Male sex is an independent risk factor for CRBSI with a hazard ratio of 1.53 (95% CI 1.19–1.96; p = 0.001).
  • The study utilized a target-trial-emulation approach to simulate earlier CVC removal.
  • Registry-based RCTs are a viable option for studying interventions in complex patient populations.

Clinical Implications

The findings suggest that minimizing CVC duration in male patients with hematological and oncological disorders could reduce the risk of CRBSI. Clinicians should consider strategies for earlier CVC removal as part of infection prevention protocols.

Conclusion

This analysis highlights the potential benefits of reducing CVC duration in male patients to decrease CRBSI rates, warranting further investigation in clinical practice.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Site-specific complications of central venous catheterization under systematic ultrasound guidance: a target trial emulation revisiting the 3SITES study
  3. Management of Positive Catheter Tip Cultures in Critically Ill Patients Without Bloodstream Infections: Insights from a Case-Cohort Analysis within the OUTCOMEREA Network
  4. Guidelines for the prevention of bloodstream infections and other infections associated with the use of intravascular catheters: part 2: central venous catheters
  5. Risk factors of central catheter bloodstream infections in intensive care units: A systematic review and meta-analysis - PMC
  6. Sex-Disaggregated Analysis of Central Venous Catheter-Related Bloodstream Infections in Patients with Cancer - PubMed
  7. American Journal of Epidemiology — Assessing the Impact of Systemic Heparin on Arteriovenous Fistula Creation Through a Target Trial Simulation
  8. Guidelines for the prevention of bloodstream infections and other infections associated with the use of intravascular catheters: part 2: central venous catheters
  9. Risk factors of central catheter bloodstream infections in intensive care units: A systematic review and meta-analysis - PMC
  10. Sex-Disaggregated Analysis of Central Venous Catheter-Related Bloodstream Infections in Patients with Cancer - PubMed

Original Source(s)

Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study

  • by Oliver Kriege, Boris Böll, Nicole Brüder, Nicola Giesen, Julia Lanznaster, Susanne Mertins, Antrea Minti, Jan-Hendrik Naendrup, Martin Schmidt-Hieber, Ruth Seggewiss-Bernhardt, Philipp Weber, Kai Wille, Jens Panse, Marcus Hentrich, Enrico Schalk

  • July 10, 2026

Related Content

Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective

Survival beyond treatment: patterns and determinants of disease-free survival in cervical cancer at a tertiary care center in India

T cell-mediated immune function in gastric cancer: a bibliometric overview of the last 20 years (2006-2025)